Q-omics provides the consensus-scored KRT20 profile across patient tissues and cancer cell-line models. KRT20 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KRT20 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, KRT20 RNA expression shows 10,164 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where KRT20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT20 survival associations across molecular data types. KRT20 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT20 RNA expression–survival associations across cancer types. High KRT20 expression shows unfavorable associations in HNSC, KIRP, LIHC, UVM, MESO and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KRT20 RNA expression.
This table summarizes KRT20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KRT20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT20 shows lower tumor expression in COAD and THCA and higher tumor expression in LUSC, KIRP, LUAD and LIHC. The COAD box plot shows higher KRT20 RNA expression in normal versus tumor tissue (log2 FC = −3.836, t-test p < 0.001).
This table shows molecular features associated with KRT20 in patient tissues and cancer cell lines. In patient samples, KRT20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
